Overview of the drug development pipeline for pruritus
It has been observed that pruritus, is an irritation of the skin that creates a sensation that makes the patient want to scratch. Pruritus can occur in any part of the body and is generally associated with dry skin. The commonly known causes of pruritus are atopic dermatitis and psoriasis. Over time, it can increase due to emotional problems such as stress and anxiety. The most-efficient approach for the pruritus treatment is emerging to be monotherapy.
According to this pipeline analysis report, most of the drug molecules in the pipeline are being developed for the treatment of pruritus. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
Drug development pipeline report for pruritus: Companies covered
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of pruritus. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are
- Alberio Pharma
- Allergan
- Amorepacific
Therapeutic assessment of the drug development pipeline for pruritus by route of administration
- Oral
- Topical
- Subcutaneous
- Topical + subcutaneous
- Inhalation
- Intradermal
- Oral + Intravenous
- Unknown
The oral route of administration (ROA) involves the administration of the drug directly into the mouth cavity and in the topical technique, the drug molecules are applied directly to the body surface such as the skin or mucous membrane, which will have a more direct effect on the target cells.
Therapeutic assessment of the drug development pipeline for pruritus
- Monotherapy
- Monotherapy + combination therapy
- Unknown
According to this pipeline analysis report, most of the molecules that are currently in the drug pipeline for pruritus are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.
Key questions answered in the report include
- What are the gene therapy molecules in the various development stages for pruritus?
- What are the companies that are currently involved in the development of drug molecules for pruritus?
- Insight into discontinued/inactive molecules with appropriate reasoning?
- What are the major regulatory authorities approving drugs in various regions?
- Detailed profiling of each active molecule
Technavio also offers customization on reports based on specific client requirement.